07 Jan 2001

Betnesol®-V Lotio (Betnesol®-V Lotio 0,1%) - Deutschland

Updated: 07 Jan 2001

Betnesol®-V Lotio 0,1%; -mite Creme 0,05% | -Creme 0,1%; -mite Salbe 0,05% | -Salbe 0,1%

Hauterkrankungen, die auf lokale Corticoidbehdlg. ansprechen.

Betnesol®-V Lotio Description, Presentation and Dosage

Betnesol®-V Lotio Description

Betnesol®-V Lotio Drug Class Description

Einzelstoffe

Betnesol®-V Lotio Drug Description

1 g enth.: Betamethason-17-valerat 1,22 mg (entspr. 1 mg Betamethason).

Betnesol®-V Lotio Generic Name

Betnesol®-V Lotio 0,1%

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio 0,1%; -mite Creme 0,05%/-Creme 0,1%; -mite Salbe 0,05%/-Salbe 0,1%

Betnesol®-V Lotio Manufacturer

Glaxo Wellcome/Cascan

Related Learning Zones

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Oral Anticoagulation Reversal Knowledge Centre

Oral Anticoagulation Reversal Knowledge Centre

The Oral Anticoagualtion Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. Content is arranged within illustrated and referenced sections including management of bleeding risk, oral anticoagulants, symposium highlights, key publication summaries and more.

This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.

This resource is not intended for healthcare professionals outside Europe.

Betnesol®-V Lotio Dosage

Betnesol®-V Lotio Adult Dosage

Cetylstearylalkohol, Methyl-4-hydroxybenzoat, Diethylenglycolmonostearat, Cetomacrogol 1000, dickfl. Paraffin, Glycerol, Isopropylalkohol.

Betnesol®-V Lotio Child Dosage


Betnesol®-V mite Creme 0,05%/-Creme 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Chlorocresol, Cetomacrogol 1000, Cetylstearylalkohol, weißes Vaselin, dickflüssiges Paraffin.

Betnesol®-V mite Salbe 0,05%/-Salbe 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Dickflüssiges Paraffin, Weißes Vaselin.

Betnesol®-V Lotio Precautions, Reactions and Contraindications

Betnesol®-V Lotio Special Precautions

Betnesol®-V Lotio Special Precautions

G 12, Z 3. Anwendung am Augenlid, Akne, Pruritus anogenitalis, Virusinfektionen, Säuglinge

Related Drugs - Dermatology

Back to top